Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape.

Partnerships and mergers are a key tool for adding value to pharmaceutical companies; helping to navigate technological limitations, address portfolio challenges and chase innovation.

This webinar, delivered in partnership with PharmaVentures, examines the trends and developments driving deal-making in the current market.

Chaired by Dr Fintan Walton, CEO & Founder of PharmaVentures, the panel included:

  • John P. FitzGerald, Senior Director, Business Development & Acquisitions, Abbvie
  • Andreas Raabe, Managing Partner & Founder, Adragos Pharma
  • William S. Marth, Managing Partner, North Ocean Ventures
  • Jansen Jacob, Vice President, PharmaVentures
  • Ozgur Akbulut, Director – Global Divestments and Contract Manufacturing Lead, Takeda

What the audience said:

“Great discussion, I wish it was 2 hours.”

“Thanks for the discussion, I also had the feeling we were just starting, so time flew by quickly! Very interesting and very professional speakers. Thanks.”

Watch: How is M&A Shifting the Pharma Manufacturing Landscape?

Access Request

Our Latest Videos

The Divestment Challenge

Watch Now

Contract Manufacturing in the Pharmaceutical Industry – Recipharm

Watch Now

Doing deals in the healthcare sector during the COVID-19 pandemic

Watch Now

White Papers

Deal Making in the Year of COVID-19

Read Now

Is Nationalism Transforming the Pharma Manufacturing Map

Read Now

M&A in COVID-19 Environment and Beyond – Keeping your perspective

Read Now

Manufacturing Operations Divestment Expertise

Having advised on the strategic direction of over 40 sites globally, we can help you to divest your manufacturing operations whilst safeguarding security of supply and retaining jobs, and assisting the new owners to build and grow profitable new businesses.

Our strategic reviews of operations have enabled our clients to engage us in the successful divestment of sites covering both small molecule and biologics capabilities across the globe.

Find out more